阿仑膦酸钠口服治疗骨质疏松症患者的服药依从性分析

Analysis of Medication Compliance in Patients with Osteoporosis Treated with Alendronate Sodium

目的探讨骨质疏松患者接受阿仑膦酸钠药物治疗依从性,并对相关因素进行分析。方法选择2016年1月至2017年1月来我院接受治疗的50例骨质疏松患者作为研究对象,所有患者都接受口服阿仑膦酸钠药物治疗,根据药物占有率将患者分为依从性好和依从性差两组,对影响依从性的相关因素进行探讨。结果 50例患者在随访1年时间内依从性好的有12例,占患者总人数24%,依从性差的患者有38例,占患者总人数76%。对各种影响药物的依从性进行分析,概括总结为无人提醒用药、骨痛、担心药物出现不良反应等。结论骨质疏松患者接受口服阿仑膦酸钠药物治疗患者依从性较差,而影响药物正常服用的因素相对较多,医护人员要能够针对各种因素选择相应的管理,提升患者药物使用依从性。

Objective To investigate the adherence of alendronate in patients with osteoporosis and analyze the related factors. Methods We selected 50 patients with osteoporosis who were treated in our hospital from January 2016 to January 2017 as study subjects. All patients were treated with oral alendronate sodium and patients were divided according to their drug share. Two groups with poor sex and poor compliance have discussed relevant factors affecting compliance. Results There were 12 patients with good compliance in the follow-up period of 1 year, accounting for 24% of the total number of patients. There were 38 patients with poor compliance, accounting for 76% of the total number of patients. Analysis of the various drug-compliances was summarized and summed up as no reminder medication, bone pain, and fear of drug side effects. Conclusion Patients with osteoporosis receiving oral alendronate drug therapy have poor compliance, and there are relatively many factors that affect the normal administration of drugs. Medical staff should be able to select appropriate management for various factors and improve patients' drug use compliance.